RedHill Biopharma Ltd. (RDHL)
| Market Cap | 12.47M |
| Revenue (ttm) | 6.53M |
| Net Income (ttm) | 23.92M |
| Shares Out | 29.70M |
| EPS (ttm) | 4.00 |
| PE Ratio | 0.11 |
| Forward PE | 1,428.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 190,389 |
| Open | 0.400 |
| Previous Close | 0.429 |
| Day's Range | 0.400 - 0.439 |
| 52-Week Range | 0.257 - 3.280 |
| Beta | 3.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 8, 2024 |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infectio... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat)1 for early COVID-19 outpatient treatment, funded through non-dilutive external sources, i...
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base Focused externally funded R...
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
TEL AVIV, Israel and RALEIGH, N.C. , April 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia 1 as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia protection until February 12, 2034 This...
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by ASPR/BARDA and NIH/NIAID, in collaboration with ...
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ion...
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
TEL AVIV, Israel and RALEIGH, N.C., Jan. 26, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Announces $8 Million Registered Direct Offering
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 25, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
USPTO issues new patent covering Talicia [1] as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI) [2] , supporting Talicia protection until May 2042 The patent is supporte...
RedHill Biopharma shares jump as Ebola treatment shows promise
RedHill Biopharma Ltd. American depositary receipts RDHL, +8.20% climbed 10% premarket on Wednesday after the company said two of its experimental drugs, when individually combined with remdesivir, sh...
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly improving potency while maintaining cell viabil...
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
TEL AVIV, ISRAEL and RALEIGH, N.C., Dec. 12, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
The new non-dilutive external funding, additional to the previously announced U.S. Government non-dilutive funding, now covers the entirety of the RHB-107 (upamostat) [1] arm of the ACESO PROTECT ada...
These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.
Stocks are poised for an upbeat finish to the best month of gains for 2023, as the fever pitch around Fed rate cuts next year grows. It's all teeing up nicely for that Santa rally, maybe.
RedHill Biopharma (RDHL) gained 216% after FDA approvals: Buy Now!
RedHill Biopharma Ltd (NASDAQ: RDHL) just received an exclusive licence for the commercialisation of Talicia. The drug is used to treat Helicobacter Pylori infections, commonly known as H- Pylori.
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
The U.S. FDA has granted five years' market exclusivity for Talicia under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, as recommended by...
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
TEL AVIV, Israel & RALEIGH, N.C. , Nov. 14, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
- Novel, oral opaganib, delivered a statistically significant increase in survival time (at 150 mg/kg BID) in a U.S. Army-funded in vivo Ebola virus study - Opaganib is believed to be the first host-d...
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
TEL AVIV, Israel & RALEIGH, N.C. , Sept. 22, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Announces FDA sNDA Approval for Talicia®
FDA approves supplemental new drug application (sNDA) for Talicia, changing dosing to a simplified three times daily (TID) regimen, which may support increased patient adherence and treatment outcomes...
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
USPTO issues Notice of Allowance for a new opaganib patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib protection until October 2035 Additionally, E...
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
RHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment; The 300-patient Phase 2 study received FDA clearance an...
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
RedHill's partner, Gaelan Medical, part of the Ghassan Aboud Group (GAG), receives marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia Gaelen placed a meaningful init...
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
RHB-107 (upamostat) accepted for inclusion in ACESO's PROTECT adaptive platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa The s...
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
TEL AVIV, ISRAEL, and RALEIGH, N.C. , July 25, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.